Background: Brucella spp. is an important zoonotic pathogen responsible for brucellosis in humans and animals. Brucella abortus A19 strain is a widespread vaccine in China. However, it has a drawback of residual virulence in animals and humans.
Methods: In this study, the BALB/c mice were inoculated with either 100 μL PBS(control group, C group), 10 CFU/mL inactivated B. abortus A19 strain (I group), 10 CFU/mL (low-dose group, L group) 10 CFU/mL live B. abortus A19 strain (high-dose group, H group), or 10 CFU/mL live B. abortus A19 strain combined with 10 CFU/mL inactivated B. abortus A19 strain (LI group). Mice were challenged with B. abortus strain 2308 at 7 week post vaccination. Subsequently, the immune and protective efficacy of the vaccines were evaluated by measuring splenic bacterial burden, spleen weight, serum IgG, interferon-gamma (IFN-γ), interleukin-4 (IL-4) percentage of CD4 + and CD8 + T cells of mice via bacterial isolation, weighing, ELISA and flow cytometry, respectively.
Results: The splenic bacterial burden and spleen weight of the mice in group LI were mostly equivalent to the mice of group H. Moreover, Brucella-specific serum IgG, IFN-γ, IL-4, and the percentage of CD4 and CD8 T cells of the LI group mice were similar to those of the H group. In the subsequent challenge test, both vaccines conferred protective immunity to wild-type (WT) 2308 strain. In addition, the levels of IL-4 and IFN-γ, CD4 and CD8 T cells in these mice were similar to those of the mice in the H group.
Conclusions: Combined immunization with low dose live vaccine and inactivated vaccine allowed to reduce the live B. abortus A19 vaccine, dose with an equivalent protection of the high-dose live vaccine.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976406 | PMC |
http://dx.doi.org/10.1186/s12917-022-03229-0 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!